19:15 , Jul 20, 2018 |  BC Week In Review  |  Financial News

Provention raises $64M IPO

Autoimmune and infectious disease company Provention Bio Inc. (NASDAQ:PRVB) raised $63.9 million on July 19 through the sale of 16 million shares at $4 in an IPO underwritten by MDB Capital Group and Dougherty &...
00:15 , Jul 20, 2018 |  BC Extra  |  Financial News

Provention raises $64M IPO

Autoimmune and infectious disease company Provention Bio Inc. (NASDAQ:PRVB) raised $63.9 million on Thursday through the sale of 16 million shares at $4 in an IPO underwritten by MDB Capital Group and Dougherty & Co....
15:31 , Jun 8, 2018 |  BC Week In Review  |  Clinical News

Daiichi planning NDA for pexidartinib on Phase III TGCT data

Daiichi Sankyo Co. Ltd. (Tokyo:4568) reported data from 120 patients with symptomatic advanced tenosynovial giant cell tumors (TGCT) in the Phase III ENLIVEN trial showing that oral pexidartinib (PLX3397) led to an overall response...
22:43 , Jun 5, 2018 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Neurology Mouse studies suggest CSF1R inhibitors could help treat age-related neurodegeneration. In a mouse model of age-related neurodegeneration, a tool compound CSF1R inhibitor decreased markers of age-related neuropathy including the numbers of thinly myelinated...
18:08 , May 11, 2018 |  BC Week In Review  |  Financial News

Provention plans IPO, reveals MacroGenics deal

Autoimmune and infectious disease company Provention Bio Inc. (Lebanon, N.J.) proposed on May 9 to raise up to $50 million in an IPO underwritten by MDB Capital Group. The company's pipeline includes several candidates in-licensed...
20:14 , May 10, 2018 |  BC Extra  |  Financial News

Provention plans IPO, reveals MacroGenics deal

Autoimmune and infectious disease company Provention Bio Inc. (Lebanon, N.J.) proposed to raise up to $50 million in an IPO underwritten by MDB Capital Group. The company's pipeline includes several candidates in-licensed from other companies...
21:28 , Feb 9, 2018 |  BioCentury  |  Emerging Company Profile

Fast boat to China

Abbisko Therapeutics aims to be first-to-market for common cancer indications in China with small molecules against clinically validated targets that are more potent than competing agents in development outside the country. Abbisko is focusing first on...
20:19 , Feb 2, 2018 |  BC Week In Review  |  Clinical News

Cabiralizumab in Phase II for pancreatic cancer, Five Prime receives $25M milestone

Bristol-Myers Squibb Co. (NYSE:BMY) began a Phase II trial to evaluate cabiralizumab (FPA008) plus Opdivo nivolumab with and without chemotherapy in patients with locally advanced or metastatic pancreatic cancer that progressed during or after one...
17:01 , Jan 31, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Colorectal cancer Mouse studies suggest combining CD40 agonists and CSF1R inhibitors could help treat colorectal cancer. In two mouse models of colon cancer, an anti-CD40 agonist antibody plus an anti-CSF1R antibody inhibitor decreased tumor...
04:59 , Nov 17, 2017 |  BC Week In Review  |  Clinical News

Five Prime reports Phase I data for cabiralizumab in pancreatic cancer

Five Prime Therapeutics Inc. (NASDAQ:FPRX) reported preliminary data from a Phase I trial of cabiralizumab (FPA008) in combination with anti-PD-1 mAb Opdivo nivolumab to treat advanced solid tumors and announced upcoming trials sponsored by partner...